ALTALYNE: payments to doctors
Payments that named ALTALYNE as the associated device or medical supply, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Johnson & Johnson?
Johnson & Johnson reported the most payments naming ALTALYNE. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $12K
- Providers
- 105
- Transactions
- 151
- Average per transaction
- $82
The per-transaction average — $82 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 105 providers the average total is $118, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $6,988 | 56.3% |
| Medical Device Business Services, Inc. | $5,431 | 43.7% |
Other products from Johnson & Johnson
The company that reported the most payments naming ALTALYNE also reports against these.
- XARELTO$68,071,435
- Tremfya$67,855,736
- SPRAVATO$27,614,037
- INVEGA SUSTENNA$19,604,416
- STELARA$17,721,584
- INVEGA TRINZA$15,954,781
- Erleada$14,804,927
- SIMPONI ARIA$13,062,639
- DARZALEX$11,334,167
- RYBREVANT$10,347,378